跳至主要内容
临床试验/CTRI/2012/09/003000
CTRI/2012/09/003000已完成4 期

A Randomized, open label, comparative, parallel group, three-arm study to evaluate the efficacy, safety and tolerability ofa combination of clobetasol, neomycin and miconazole versus combination of betamethasone, clotrimazole, neomycin versus combination of betamethasone, gentamicin, miconazole in patients with any type of eczematous disorderassociated with underlying tinea / yeast infection

Abbott Healthcare Pvt Ltd1 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2012年2月7日最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
54
试验地点
1
主要终点
•Improvement in clinical score from baseline

研究概览

简要总结

This study is done to evaluated the efficacy and safety of a combination of clobetasol, neomycin and miconazole versus combination of  betamethasone, clotrimazole, neomycin versus combination of betamethasone, gentamicin, miconazole in patients with any type of eczematous disorder associated with underlying tinea / yeast infectionxml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /

研究设计

研究类型
Interventional
分配方式
Permuted block randomization, fixed
盲法
Not Applicable

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • •Patients aged 18 years and above diagnosed with any type of eczematous disorder associated presenting clinical features of underlying tinea/yeast infection •Patients who agree to adhere to the study design •Patients who give their consent for participation in this study.

排除标准

  • •Pregnant or lactating females •Indications for use of systemic therapy •Patients sensitive to corticosteroids •Patients who have immune deficiency, hepatic or renal impairment •Patients who have been on any therapy within 1 month prior to enrollment in the study •Patients who are using any other concomitant therapy.

结局指标

主要结局

•Improvement in clinical score from baseline

时间窗: Baseline, Day3, Day5 and Day7

次要结局

  • •Improvement in scaling and inflammation(•Improvement in burning and itching)

研究者

申办方类型
Pharmaceutical industry-Global

研究点 (1)

Loading locations...

相似试验